Application of methoxy flavonoid compound in preparation of anti-vitiligo medicine

A technology of methoxyflavones and compounds is applied in the field of preparation of anti-vitiligo drugs, and can solve the problems of non-universal treatment methods, difficult clinical promotion of photochemotherapy, and death of melanocytes.

Pending Publication Date: 2021-12-10
张波
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Narrow-band UVB treatment (NB-UVB) has high phototoxicity, which induces the accumulation of melanin and also induces the death of melanocytes
The clinical promotion of 308nm excimer laser, helium-neon laser and photochemotherapy is difficult, and the treatment methods are not universal
Invention patent CN201210045334.1 "Venonia flavonoid components and its preparation method and application" discloses seven flavonoid components such as Butacein and Butacein isolated from Vernonia vernonia, and it is found that these compounds have The effect of treating vitiligo, but the superiority of the flavone with methoxyl group is not clear, and the invention patent only involves the migration of melanocytes, that is, the accumulation of melanocytes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of methoxy flavonoid compound in preparation of anti-vitiligo medicine
  • Application of methoxy flavonoid compound in preparation of anti-vitiligo medicine
  • Application of methoxy flavonoid compound in preparation of anti-vitiligo medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] For details of experimental materials and animals, see the content of the appeal.

[0048] The name and treatment situation of each group in this embodiment are as follows: (1) blank control group (Ctrl); (2) methoxysalen positive drug group (8-MOP, 25 μ mol / L); (3) kaempferol group (2 -64 μmol / L); (4) isorhamnetin group (4-64 μmol / L). Place them in water at a temperature of 24-28°C for feeding, light for 14 hours a day, and place them in darkness for 10 hours. The specific treatment is as follows:

[0049] 100 adult zebrafish aged 4-12 months were randomly divided into 4 groups, 25 in each group. Control group: treated with 550nmol / L new copper reagent for 20 days, natural restoration of melanin regeneration for 3 days; positive control group: treated with 550nmol / L new copper reagent for 20 days, 25μmol / L methoxysalen (8-MOP) for 3 days Isorhamnetin group: treated with 550nmol / L new copper reagent for 20 days, treated with different concentrations of isorhamnetin (...

Embodiment 2

[0051] The name and treatment situation of each group in this embodiment are as follows: (1) blank control group (Ctrl); (2) methoxysalen positive drug group (8-MOP, 25 μ mol / L); (3) kaempferol group (2 -64 μmol / L); (4) isorhamnetin group (4-64 μmol / L). Place them in water at a temperature of 24-28°C for feeding, light for 14 hours a day, and place them in darkness for 10 hours. The specific treatment is as follows:

[0052] 100 adult zebrafish aged 4-12 months were randomly divided into 4 groups, 25 in each group. Control group: treated with 550nmol / L new copper reagent for 20 days, natural restoration of melanin regeneration for 3 days; positive control group: treated with 550nmol / L new copper reagent for 20 days, 25μmol / L methoxysalen (8-MOP) for 3 days Isorhamnetin group: treated with 550nmol / L new copper reagent for 20 days, treated with different concentrations of isorhamnetin (Ire) for 3 days; kaempferol group: treated with 550nmol / L new copper reagent for 20 days, us...

Embodiment 3

[0055] The name and processing situation of each group in this embodiment are as follows:

[0056] (1) blank control group (Ctrl); (2) methoxysalen positive drug group (8-MOP, 25 μmol / L); (3) kaempferol group (2-64 μmol / L); (4) isorhamna Plain group (4-64μmol / L). Place them in water at a temperature of 24-28°C for feeding, light for 14 hours a day, and place them in darkness for 10 hours. Zebrafish aged 4 to 12 months were taken, and their caudal fins were obliquely cut off. They were treated with kaempferol, isorhamnetin and methoxsalen respectively for 10 days, and the newborn primordia of the zebrafish tail were taken for horizontal frozen tissue sections, stained with hematoxylin. solution for staining, the results are as follows image 3 .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of methoxy flavonoid compound in preparation of anti-vitiligo medicine. According to the application of the methoxy flavonoid compound in preparation of the anti-vitiligo medicine, the methoxy flavonoid compound with 2-phenylchromone mother nucleus has an anti-vitiligo effect and represents compounds including kaempferide, isorhamnetin and kaempferol 3, 4 '-dimethyl ether. The methoxyflavone compound promotes regeneration and neogenesis of melanocytes and induces accumulation of melanin by promoting expression of key genes in a melanogenesis pathway, and maintains melanin steady state and reduces decomposition of original melanin cytochrome by up-regulating expression of melanin steady state related protein adcy6; meanwhile, the increase of active oxygen under physiological dose is induced, the expression of glutathione synthesized gclm, gclc and other related genes is down-regulated, melanin metabolism is reduced, so that the effect of treating vitiligo is achieved, and the methoxy flavonoid compound has important value and development prospect in the research and development of vitiligo treatment medicine.

Description

technical field [0001] The invention relates to a new application of methoxyflavonoids, that is, the application in the preparation of anti-vitiligo drugs. Background technique [0002] Vitiligo (vitiligo) is an acquired pigment disorder of unknown cause, without gender and race differences, and with no age differences in the onset population. Its clinical feature is that the patient forms white or pale white plaques with hypopigmentation or disappearance with relatively clear borders. The skin color at the edge of the lesion and its vicinity usually remains unchanged or slightly darkened. become white. According to the European consensus, it can be divided into two categories: segmental (SV) and non-segmental (NSV). Vitiligo is one of the three major intractable skin diseases in the world. Its global incidence is about 0.5%-2%, and the incidence in some areas can reach 2%-3%. The incidence in my country is about 0.1%-2%. Although vitiligo is not a fatal disease, the expo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61K47/18A61K47/20A61P17/00
CPCA61K31/352A61K47/183A61K47/20A61P17/00
Inventor 张波黄思露王晓琴
Owner 张波
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap